Skip to main content
Metal-Based Drugs logoLink to Metal-Based Drugs
. 2001;8(1):19–28. doi: 10.1155/MBD.2001.19

Knigth's Move in the Periodic Table, From Copper to Platinum, Novel Antitumor Mixed Chelate Copper Compounds, Casiopeinas, Evaluated by an in Vitro Human and Murine Cancer Cell Line Panel

Isabel Gracia-Mora 1,2, Lena Ruiz-Ramírez 1,, Celedonio Gómez-Ruiz 2,3, Mabel Tinoco-Méndez 2, Adriana Márquez-Quiñones 1, Laura Romero-De Lira 1, Álvaro Marín-Hernández 1, Lucía Macías-Rosales 2, Ma Elena Bravo-Gómez 1
PMCID: PMC2365248  PMID: 18475972

Abstract

We synthesized a novel anticancer agents based on mixed chelate copper (II) complexes, named Casiopeínas® has of general formula [Cu(N-N)(N-O)H2O]NO3 (where, N-N = diimines as 1,10- phenanthroline, 2,2-bipyridine, or substituted and N-O=aminoeidate or [Cu(N-N)(O-O)H2O]NO3 (where NN= diimines as 10-phenanthroline, 2,2-bipyridine or substituted Casiopeínas I, II, IV, V, VI, VII VIII and O-O=acetylacetonate, salicylaldehidate Casiopínas III). We evaluated the in vitro antitumor activity using a human cancer cell panel and some nurine cancer cells. Eleven Casiopeinas are evaluated in order to acquire some structure-activity correlations and some monodentated Casiopeinäs analogues; cisplatinum was used as control drug. The 50% growth inhibition observed is, in all cases reach with concentrations of Casiopeina's 10 or 100 times lower than cisplatinum. In a previous work we reported the induction of apoptosis by Casiopeina II. The results indicate that Casiopeinass are a promising new anticancer drug candidates to be developed further toward clinical trials.

Full Text

The Full Text of this article is available as a PDF (1.4 MB).


Articles from Metal-Based Drugs are provided here courtesy of Wiley

RESOURCES